Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 196Myelodysplastic Syndromes 128Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Leukemia, Lymphocytic, Chronic, B-Cell 102Leukemia 102Lymphoma 86Multiple Myeloma 81Lymphoma, Non-Hodgkin 80Hematologic Neoplasms 65Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Hodgkin Disease 62Recurrence 52Lymphoma, B-Cell 40Lymphoma, Mantle-Cell 39Myeloproliferative Disorders 36Lymphoma, Follicular 35Melanoma 34Lymphoma, Large B-Cell, Diffuse 31Burkitt Lymphoma 31Graft vs Host Disease 28Neoplasms, Plasma Cell 24Primary Myelofibrosis 23Ovarian Neoplasms 23Lymphoma, B-Cell, Marginal Zone 23Anemia, Refractory, with Excess of Blasts 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 17Lymphoma, T-Cell 16Neuroblastoma 15Neoplasms 14

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × fludarabine × Clear all
NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
20 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡